This article introduces a strategy for stabilizing and redispersing layered double hydroxide (LDH) nanoparticles by crosslinking bovine serum albumin (BSA) coated onto the surface.
Introduction
Due to their potential application in biomedical therapeutics, nanoparticles have attracted intense scientific interest. Nanoparticles normally have at least one dimension in the range of 1-100 nm, and can therefore readily enter the cell microenvironment. [1, 2] Stabilization of nanoparticles is a fundamental requirement necessary for successful use in clinical applications. Upon intravenous injection, nanoparticles often interact with biological environments that consist of biomolecules such as proteins, sugars, and electrolytes. These interactions can lead to nanoparticle aggregation and blockage of blood vessels and capillaries. Therefore, it is of particular importance that nanoparticles avoid aggregation in the in vivo situation. [3] [4] [5] The development of nanotechnology allows researchers to rationally engineer nanoparticles for targeted delivery, prolonged circulation half-life, improved therapeutic index and reduced immunogenicity. [6] [7] [8] It is therefore desirable to engineer nanoparticles with high colloidal stability in biological fluids. Additionally, maximal surface accessibility for drug/gene loading and delivery is desirable.
Previously, we reported that layered double hydroxide (LDH) can effectively deliver drug/DNA into several types of cells including fibroblasts, HEK 293, CHO cells and neurons. [9] [10] [11] LDH is a family of anionic clays, and can be found in nature and also readily synthesized in the laboratory. [12, 13] Similar to hydrotalcite, the LDH composition can be expressed as the formula [M of LDH nanoparticles is a hexagonal, plate-like, stacked layer structure, with a lateral diameter tailored from 50 to 300 nm. [14] With the exchangeable property, the LDHs are able to load various negatively charged therapeutics, such as DNA and RNA, anionic drugs and peptide/proteins. Many investigations show that LDHs are a potential drug and gene delivery candidate as they have many intrinsic advantages, including good biocompatibility, low cytotoxicity, high drug loading and controllable drug release mechanism. [15] [16] [17] [18] [19] [20] [21] However, in vivo applications of these nanoparticles have been hampered by their tendency to aggregate in biological environments, resulting in inflammatory responses or death. Therefore, it is necessary to improve the stability of LDH nanoparticles for in vivo applications.
Several methods have been used to increase stability of colloidal systems, including surfactant molecule attachment on the nanoparticle surface, surface modification of functional groups and modification designed to enhance stability via steric repulsion and electrostatic repulsion. [22] For example, silver nanoparticles were modified with two surfactants (sodium dodecyl sulfate and polyoxyethylenesorbitane monooleate-Tween 80) to improve anti-aggregation properties. [23] PEGylation is an often used strategy to maintain colloidal stability via the steric effect. [22, 24, 25] It is well-known that charged nanomaterials adsorb strongly on oppositely charged surfaces, and they are widely used to stabilize the nanoparticles. [26] Recently, we used BSA to coat LDH nanoparticles and found that these LDH-BSA complexes are colloidally stable in various electrolyte solutions. [27] Chemical crosslinking is one of the highly versatile methods to create a network on the nanoparticle surface by crosslinking functional groups of the surface molecules. Crosslinking with the amine-carboxylic acid, isocyanate-OH/NH 2 reaction and Schiff base formation, [28, 29] can prevent aggregation via steric repulsion. Dynamic light scattering (DLS) is a common method to study aggregation and colloid stability of various nanoparticles, which was thus used in this research. [30, 31] Scheme 1. Schematic illustration of BSA-coating onto LDH nanoparticles and subsequent GTA crosslinking.
It is ideal to design a well-dispersed colloidal system over a wide range of buffer conditions with ready redispersity, while simultaneously having surface accessibility for loading therapeutics. Our previous stabilization of LDH nanoparticles with BSA was achieved in specific buffer conditions (Step A in Scheme 1), but the BSA-LDH complexes became unstable at low concentrations. Moreover collected BSA-LDH particles are poorly redispersed in aqueous solution. Therefore, in this study, we crosslinked BSA after coating onto the LDH surface with glutaraldehyde (GTA) ( Step B in Scheme 1) and demonstrated that this crosslinked BSA-LDH system has an enhanced colloidal stability and excellent redispersity. The optimized crosslinking only consumed a small portion of functional groups in BSA, leaving the majority available for further surface modification. Note that the crosslinked LDHs showed cytotoxicity similar to LDH alone, indicating their good biocompatibility for biomedical applications.
Materials and Methods

Materials
Complementary strands of dsDNAs were purchased from GeneWorks and annealed at 75 °C for 10 min. One strand of the duplex was covalently coupled to the cy3 fluorophore at the 5′ end before annealing. Glutaraldehyde (GTA) solution (25%) was bought from Ajax Finechem, and other chemicals and reagents from Sigma-Aldrich if not illustrated specifically.
Water used in experiments was deionized Milli-Q water.
Synthesis of LDH nanoparticles
Mg 2 Al-Cl-LDH (pristine LDH) was prepared using a co-precipitation-hydrothermal treatment method, as reported previously. [17, 32] In brief, LDH was synthesized by mixing 40 ml NaOH 
Crosslinking of BSA coated on LDH
Two mililiters of 4 mg/ml LDH suspension was added into 2 ml of 10 mg/ml BSA solution 
Quantification of active amino groups on crosslinked BSA
GTA was applied as the crosslinking agent to react with BSA (as shown in Scheme 2). The determination of unreacted amino groups was performed using the reaction of TNBS (2, added into the reaction mixture and shaken at 500 rpm for 2 h at 40 °C. The solution was then assayed by recording the absorbance at 343 nm. The content of free amino groups on the crosslinked BSA surface was calculated in relation to BSA treated in the same manner as described above but without using GTA.
Scheme 2. Schematic illustration of BSA reaction with GTA
Colloidal stability test
The size and polydispersity index (Pdi) of BSA-LDH and BSA-LDH-GTA at different concentrations (diluted for 0, 10, 160, and 320 times) were measured on a Nano Zetasizer (Nano ZS, MALVERN Instruments). The same volume of PBS was then mixed with BSA-LDH or BSA-LDH-GTA under vigorous stirring for 30 min and the particle size distribution was monitored similarly. LDHs in water and in PBS were also measured for the particle size distribution on a Nano Zetasizer instrument.
Redispersion ability test
After centrifugation, BSA-LDH or BSA-LDH-GTA was collected and frozen in liquid nitrogen for 10 min, and then freeze-dried for 24 h, followed by being redispersed in water under gentle ultrasonication. The particle size distribution of water-redispersed particles (equilibrate to the original concentration) was measured and then compared with the initial one in the suspension.
Nucleic acid association with LDH
The association of dsDNA with LDH was conducted by mixing dsDNA with pristine LDH, BSA-LDH, and BSA-LDH-GTA at the LDH: DNA mass ratio of 40:1 using light agitation at 37 °C overnight.
In vitro cytotoxicity test and cellular uptake
Rat vascular smooth muscle cells (SMC) and human breast tumour cell line (MCF-7) were seeded in a 96-well or 6-well plate at a density of 4-5 × 10 4 cells/cm 2 in growth medium (Medium 199 and DMEM medium respectively, containing 10% foetal calf serum, 10 U/ml penicillin and 10 µg/ml streptomycin), and incubated at 37 °C in a humidified atmosphere with 5% CO 2 .
Cytotoxicity of BSA-LDH-GTA was examined by the MTT (Sigma) assay. Twenty-four hours after seeding, the cells were treated with growth medium containing BSA-LDH-GTA Cell uptake efficacy of BSA-LDH and BSA-LDH-GTA was determined by flow cytometry (BD LSM II). Twenty-four hours after cell seeding, the cells were treated with growth medium containing BSA-LDH-dsDNA-cy3 or BSA-LDH-dsDNA-cy3-GTA for 24 h (both contained the same amount of dsDNA-cy3). After centrifugation and washing with PBS for three times, the cells were fixed in 2% paraformaldehyde/PBS and analyzed on the flow cytometer.
Characterization
The particle size distribution and zeta potential of LDH, BSA-LDH, and BSA-LDH-GTA in aqueous solutions were measured on a Nano Zetasizer instrument. 
Results and Discussion
BSA-coated LDH nanoparticles and redispersity
As shown in Figure 1A and Figure S1 , after hydrothermal treatment, a monodispersed LDH nanoparticle suspension was obtained with an average hydrodynamic diameter of 105 nm and a Pdi of 0.211, in agreement with the previous report. [33] When the LDH suspension was added into electrolyte solution (e.g. PBS or culture medium), LDH nanoparticles formed aggregates with the average particle size being in the micrometer range (>1000 nm) in PBS (not shown) and 400 nm in culture medium ( Figure 1A ), respectively. Our previous work has successfully developed a BSA coating method to prevent aggregation of LDH nanoparticles in PBS or culture medium. [27] As shown in Figure 1A , the particle size distribution of BSA-LDH (5:2) in PBS or culture medium was similar to that of BSA-LDH originally suspended in water. These phenomena showed that coating LDH with BSA was able to prevent aggregation of LDH nanoparticles in electrolyte solutions. As we previously reported, the aggregation was probably due to the bridging effect of adsorbed serum molecules from the medium or reduced electrostatic repulsion caused by adsorption of ions on the LDH surface that counteracts the intrinsic surface charge of LDHs. We believe that
BSA coating probably provides a strong steric repulsion and is able to prevent LDH particle aggregation in electrolyte solutions and the culture medium. Figure 1B shows the redispersion ability of BSA-LDH after centrifugation and freezedrying compared with the initial BSA-LDH suspension. The data revealed that the redispersed BSA-LDH had many large aggregates with the size > 1000 nm, different from that in BSA-LDH suspension (average particle size of 171 nm). The BSA-LDH suspension contains many free BSA molecules, which are in adsorption equilibrium with the BSA adsorbed on the LDH surface, thereby maintaining colloidal stability. Freeze-drying following centrifugation removes the free BSA from solution, preventing equilibrium being reached again during redispersion, resulting in incomplete dispersion. As freeze-drying techniques are an essential process in the manufacture pharmaceuticals, it is of great importance to enhance the redispersion ability of BSA-LDH complexes.
Colloidal stability of BSA-coated LDH nanoparticles
As shown in Figure 2 , BSA-LDH (the BSA/LDH mass ratio = 5:2, the LDH concentration = 2000 µg/ml) had an average size of 176 nm and a Pdi of 0.229. At this BSA/LDH mass ratio, there were about 0.7 mg of BSA adsorbed onto 1.0 mg of LDH and 3.6 mg of free BSA in 1.0 ml aqueous suspension. [27] When this BSA-LDH suspension was diluted 10 times (the LDH concentration = 200 µg/ml), the particle size distribution of BSA-LDH remained the same (the average size = 173 nm, and Pdi = 0.230). However, when the BSA-LDH suspension was continuously diluted, the particle average size increased to 298 nm (the LDH concentration = 12.5 µg/ml) and then 864 nm (the LDH concentration = 6.3 µg/ml). This aggregation can be again explained by the disturbed equilibrium between BSA adsorbed on LDH and free BSA in solution after dilution. With the addition of water, the concentration of free BSA in solution decreases. For example, the concentration of free BSA was reduced from 3.6 mg/ml to only 22.5 µg/ml in the suspension diluted for 160 times. Thus some adsorbed BSA desorbs from the surface to solution. As BSA desorption continues, LDH particles would share BSA molecules via the protein bridging effect, which leads to particle aggregation. 
Enhanced colloidal stability by crosslinking BSA on the LDH surface
We next employed a crosslinking strategy to increase BSA-LDH stability and redispersity.
First, the effectiveness of crosslinking BSA by using GTA was examined. The amount of unreacted amino groups deceased significantly with increasing GTA amount used (Table 1 and Figure S2 ), indicating that there was a progressive degree of crosslinking. [34] After addition of 40 µl 5% GTA or more, very little change in the unreacted amino group number was observed, indicating that all available amino groups had participated in the GTA crosslinking. The number of amino groups on the crosslinked BSA was determined. GTA volumes of 1 to 100 µl for quantitative cross-linking of the 59 amino groups in the BSA molecules were employed in these tests.
To determine the optimized GTA concentration for stabilizing the BSA-LDH nanohybrids, a series of BSA: GTA molar ratios (1:0.5, 1:15, 1:45, and 1:135) were used and the obtained suspensions were subjected to dilution tests. As shown in Figure 3A and Table S2 , the average particle size of BSA-LDH-GTA was around 170 nm at the BSA/GTA ratio of 1:135 when diluted from 40 to 640 times. In all other cases (BSA:GTA molar ratio = 1:0.5, 1:15 and 1:45), the average particle size increased, indicating that some aggregation still took place even though the adsorbed BSA molecules were partly crosslinked. Therefore, the molar ratio of BSA: GTA (1:135) was applied in the following experiments. The particle size distribution of BSA-LDH-GTA (1:135) also remained the same after 10-, 160-and 320-fold dilution ( Figure 3B ), in sharp contrast with that presented in Figure 2 .
This suggests that the crosslinking of surface adsorbed BSA by GTA can avoid/minimize the release of adsorbed BSA into solution, thus preventing LDH particles from aggregation caused by dilution. Interestingly, the BSA: GTA molar ratio of 1:135 corresponded to 5 µl 5% GTA (Table 1) , which means that there were 33 amino groups available per BSA molecule after crosslinking. Therefore, the optimized BSA/GTA molar ratio of 1:135 ensures sufficient colloidal stability of the LDH nanoparticle system, and at the same time maintains an adequate number of free amino groups/BSA for further modification and/or loading. As shown in Figure 4 and Table S2 , the average size of the initial BSA-LDH particles in water or PBS remained at about 175 nm when the suspension was diluted up to 80-fold, but increased dramatically when diluted 320-fold. In contrast, BSA-LDH-GTA nanohybrids remained the same size (around 180 nm) in both water and PBS when diluted. This stability can be attributed to the crosslinking of BSA, which immobilizes BSA onto the LDH surface and maintains the colloidal stability through steric repulsion. The comparison clearly demonstrates the enhancement of BSA-LDH colloidal stability through the crosslinking strategy. Figure 5 . Particle size distribution of BSA-LDH-GTA and redispersed one. Each experiment was carried out in 3 independent experiments.
Improved redispersity of BSA-LDH after crosslinking
As shown in Figure 5 and Table S1 , the redispersity of freeze-dried BSA-LDH-GTA hybrids in water was obviously improved. After BSA-LDH-GTA hybrids were redispersed with gentle ultrasonication, the particle size distribution with an average particle size of 219 nm and a Pdi of 0.323 was very similar to that for the parent BSA-LDH-GTA hybrids. This redispersity is markedly better than that for un-crosslinked BSA-LDH ( Figure 1B) under the same conditions. The crosslinked BSA on the LDH surface was now immobilized with a more rigid configuration, which may keep the freeze-dried particles better separated. As a result, the BSA-LDH-GTA hybrids were more readily redispersed in water. This property is of importance to the pharmaceutical sector, because freeze-drying technique is essential for the storage and transport of pharmaceuticals.
Cytotoxicity of BSA-LDH-GTA
In general, the viability of cancer cell line, MCF-7, and smooth muscle cells (SMCs) after exposure to BSA-LDH-GTA ( Figure 6A , B) gradually decreased with the increasing particle concentration and the incubation time. [32] The viability of SMCs treated with 10-100 µg/ml of BSA-LDH-GTA hybrids did not change significantly after the first day of incubation, but decreased by 20 to 30% at day 2 to 3. In contrast, a significant reduction in cell viability was observed in BSA-LDH-GTA at the concentrations of 200-500 µg/ml of BSA-LDH-GTA at day 2-3.
BSA-LDH-GTA at 10-200 µg/ml did not affect the MCF-7 cell viability significantly during the 3-day incubation period (> 80%), while 500 µg/ml significantly reduced their viability after 2 to 3 days. Compared with LDH's cytotoxicity reported previously (cell viability were over than 90% within 3 days incubation at the concentration range of 10-500 µg/ml), [35] BSA-LDH-GTA hybrids were slightly more toxic to SMCs, but still suggesting a good biocompability. The increased cytotoxicity is possibly due to the unreacted aldehyde groups in GTA that are known to induce some toxicity. [36] In most in vitro tests for drug and gene delivery, [33, 37, 38] the LDH concentration is normally in the range of 10-100 µg/ml. Thus this toxicity test has demonstrated that the BSA-LDH-GTA delivery platform has negligible toxicity for SMCs and the cancer cell line MCF-7 in our in vitro assay. was used to assess statistical significance. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Cellular uptake
According to our previous report, a five-fold excess of LDH nanoparticles is sufficient to ensure maximum association of dsDNA with LDHs. [26] The conditions required for the same amount of dsDNA intercalation were confirmed by gel electrophoresis ( Figure S3) . Therefore, the LDH:dsDNA mass ratio of 40:1 was used to ensure BSA-LDH and BSA-LDH-GTA to contain the same amount of dsDNA. As shown in Figure 7 , after 24 h incubation, the percentage of SMCs internalizing fluorescent BSA-LDH-dsDNA-cy3-GTA particles was about 67%, 30% lower than that for cells internalizing BSA-LDH-dsDNA-cy3 (96%). MCF-7 cells took up 17% less BSA-LDHdsDNA-cy3-GTA particles (68%) than BSA-LDH-dsDNA-cy3 (85%). The results indicate that GTA crosslinking inhibits cell uptake to some degree compared to uncrosslinked nanoparticles. The possible reason is loss of functional positive amino groups on the surface of BSA-LDH nanoparticles after crosslinking. The positive charges on the particle surface increases cell surface affinity. As previously reported, increasing the amount of amine groups facilitates cellular uptake of nanoparticles by various cell lines. [39] Although BSA-LDH-GTA
showed slight inhibition to cell uptake compared to BSA-LDH, the GTA crosslinking strategy provides much higher colloidal stability and much easier redispersity of LDH nanoparticles for more potential bioapplications in vivo.
It should be mentioned that the loaded dsDNA could be released via the anion exchange with the cytosol anions or through dissolution of LDH in the endosome/lysosome, as proposed previously.
[38]
Conclusions
Size control of LDH nanoparticles is a challenging problem for clinical applications. This work introduced a crosslinking strategy to stabilize LDH nanoparticles based on the previous BSA coating strategy, and crosslinked BSA-LDH hybrids had improved colloidal stability and redispersity of freeze-dried samples. Although the cytotoxicity of BSA-LDH-GTA increased especially at the concentration of 500 µg/ml when compared to LDH cytotoxicity, BSA-LDH-GTA at concentrations of 10-200 µg/ml had minimal effect. Importantly, our modified LDH nanoparticles can be further conjugated with functional molecules to promote target delivery to specific cells types. Overall, this new crosslinking strategy promises a more stable BSA coated LDH nanoparticles system with broad applications in vitro and in vivo. 
